New drug aims to shield kidneys and heart in diabetic patients
NCT ID NCT07326631
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug finerenone can slow kidney function decline and lower heart failure risk in 120 adults with type 2 diabetes and chronic kidney disease. Participants must already be on standard blood pressure medications. The study will measure changes in kidney function, heart failure events, and safety issues like high potassium levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE (DKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?